Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 46.75 times its estimated earnings per share for the ongoing year.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The group usually releases earnings worse than estimated.